La vendita allo scoperto per Waters dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Waters. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Waters (NYSE:WAT) Azioni, Report sulle vendite allo scoperto

Waters

Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.

Waters Corp

AMD MSCI WTR ESG ETF

Energous Corp

AMND MSCI WTR D ETF

Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) is preparing to release its quarterly earnings on Friday, 2024-11-01. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Waters to report an earnings per share (EPS) of $2.68.
Anticipation surrounds Waters's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.07 in the last quarter, leading to a 4.83% increase in the share price on the following day.
Here's a look at Waters's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.56</td>
<td>2.10</td>
<td>3.55</td>
<td>2.55</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.63</td>
<td>2.21</td>
<td>3.62</td>
<td>2.84</td>
</tr>
<tr>
<td>Price Change %</td>
<td>5.0%</td>
<td>-1.0%</td>
<td>-2.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730383280_0.png" alt="eps graph" />
<h3>Waters Share Price Analysis</h3>
Shares of Waters were trading at $326.59 as of October 30. Over the last 52-week period, shares are up 24.59%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Perspectives on Waters</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Waters.
Waters has received a total of 4 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $365.0, the consensus suggests a potential 11.76% upside.
<h3>Peer Ratings Overview</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Avantor, Illumina and Revvity, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>The prevailing sentiment among analysts is an Outperform trajectory for Avantor, with an average 1-year price target of $28.67, implying a potential 91.22% downside.</li>
<li>As per analysts' assessments, Illumina is favoring an Neutral trajectory, with an average 1-year price target of $167.41, suggesting a potential 48.74% downside.</li>
<li>The consensus outlook from analysts is an Outperform trajectory for Revvity, with an average 1-year price target of $135.0, indicating a potential 58.66% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
The peer analysis summary presents essential metrics for Avantor, Illumina and Revvity, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Waters</td>
<td>Buy</td>
<td>-4.33%</td>
<td>$420.29M</td>
<td>10.70%</td>
</tr>
<tr>
<td>Avantor</td>
<td>Outperform</td>
<td>-2.36%</td>
<td>$581.50M</td>
<td>1.73%</td>
</tr>
<tr>
<td>Illumina</td>
<td>Neutral</td>
<td>-5.44%</td>
<td>$721M</td>
<td>-55.45%</td>
</tr>
<tr>
<td>Revvity</td>
<td>Outperform</td>
<td>-2.45%</td>
<td>$385.51M</td>
<td>0.70%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Waters ranks highest in Gross Profit and Return on Equity among its peers. However, it ranks lowest in Revenue Growth. Overall, Waters is positioned in the middle compared to its peers based on the provided metrics.
<h3>Get to Know Waters Better</h3>
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.
<h3>A Deep Dive into Waters's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Waters's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -4.33%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Waters's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 20.15% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Waters's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.7% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Waters's ROA stands out, surpassing industry averages. With an impressive ROA of 3.19%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Waters's debt-to-equity ratio stands notably higher than the industry average, reaching 1.48. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<a href="https://www.benzinga.com/quote/WAT/earnings">To track all earnings releases for Waters visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

A Look Ahead: Waters's Earnings Forecast

<ul>
<li>Waters new&nbsp;LC-MS&nbsp;grade reagents, enzymes, and software simplify large molecule RNA analysis to accelerate and improve development of mRNA vaccines, personalized cancer therapies, and innovative drugs for genetic disorders.</li>
<li>Novel digestion enzymes deliver complete RNA sequence coveragei&nbsp;for more confident characterization, while new LC-MS-grade reagents increase sensitivity and improve detection accuracy of RNA components.ii</li>
<li>New&nbsp;waters_connect&#x2122; MAP Sequence software accelerates RNA oligonucleotide mapping using semi-automated workflows that reduce data processing time over manual techniques, enabling routine monitoring of key product attributes.</li>
</ul>
MILFORD, Mass., Oct. 10, 2024 /PRNewswire/ -- Waters Corporation (NYSE:&nbsp;WAT) today introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LC-MS) analysis. When used together in a workflow, these bioseparations tools help accelerate and improve the development of innovative large molecule RNA-based pharmaceuticals, such as CRISPR sgRNA and mRNA therapeutics.

Biotech

News

General

Waters Announces Its New Bioseparations Tools Accelerate And Improve Development Of RNA-based Vaccines And Therapies Using LC-MS Analysis

Throughout the last three months, 7 analysts have evaluated Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $354.0, with a high estimate of $415.00 and a low estimate of $300.00. This upward trend is evident, with the current average reflecting a 9.2% increase from the previous average price target of $324.17.
<img src="https://www.benzinga.com/files/images/story/2024/1728417638_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Waters among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$415.00</td>
<td>$355.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$355.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$360.00</td>
<td>-</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$363.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$300.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Justin Bowers</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$310.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Puneet Souda</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$375.00</td>
<td>$325.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Waters. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Waters compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Waters's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Waters's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WAT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Waters analyst ratings.</a>
<h2>Delving into Waters's Background</h2>
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.
<h3>Breaking Down Waters's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Waters's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -4.33%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 20.15%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Waters's ROE excels beyond industry benchmarks, reaching 10.7%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.19%, the company showcases effective utilization of assets.
Debt Management: Waters's debt-to-equity ratio surpasses industry norms, standing at 1.48. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Forecasting The Future: 7 Analyst Projections For Waters

Jefferies analyst Tycho Peterson upgrades Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) from Hold to Buy and raises the price target from $355 to $415.

Upgrades

Price Target

Jefferies Upgrades Waters to Buy, Raises Price Target to $415

Evercore ISI Group analyst Vijay Kumar maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a In-Line and raises the price target from $335 to $355.

Evercore ISI Group Maintains In-Line on Waters, Raises Price Target to $355

TD Cowen analyst Dan Brennan maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Hold and raises the price target from $325 to $363.

TD Cowen Maintains Hold on Waters, Raises Price Target to $363

Waters Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) reported upbeat second-quarter earnings, but lowered its<a href="https://www.benzinga.com/quote/WAT/earnings"> FY24 outlook on Wednesday</a>.
Waters reported quarterly earnings of $2.63 per share which beat the analyst consensus estimate of $2.56 per share. The company reported quarterly sales of $708.529 million which beat the analyst consensus estimate of $700.079 million.
&#8220;Our team executed well to deliver second quarter results that exceeded both our top-line and bottom-line reported guidance,&#8221; said Dr. Udit Batra, President &amp; CEO, Waters Corporation. &#8220;Our margins remained resilient, thanks to our disciplined approach to operational management, which offset headwinds from volume, currency, and inflation.&#8221;
Waters said it now sees FY24 adjusted earnings of $11.55 to $11.65 per share, versus earlier forecast of $11.75 to 12.05 per share. The company now expects sales growth outlook of -2.2% to -0.7%.
Waters shares gained 2.8% to trade at $345.82 on Thursday.
These analysts made changes to their price targets on Waters following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58cfe564b85e9300015ce42f/puneet-souda">Leerink Partners analyst Puneet Souda</a> upgraded Waters from Market Perform to Outperform and boosted the price target from $325 to $375.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e53ccccece4e600011fda74/justin-bowers">Deutsche Bank analyst Justin Bowers</a> maintained the stock with a Hold and lowered the price target from $330 to $310.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5ea2ec210cd8860001a1b1ce/luke-sergott">Barclays analyst Luke Sergott</a> maintained Waters with an Underweight rating, while raising the price target from $275 to $300.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40101200/top-3-health-care-stocks-that-are-set-to-fly-this-quarter">Top 3 Health Care Stocks That Are Set To Fly This Quarter</a></li>
</ul>

Markets

Trading Ideas

These Analysts Revise Their Forecasts On Waters After Q2 Results

Ratings for Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Waters and provided 12-month price targets. The average target is $317.44, accompanied by a high estimate of $375.00 and a low estimate of $275.00. Witnessing a positive shift, the current average has risen by 0.46% from the previous average price target of $316.00.
<img src="https://www.benzinga.com/files/images/story/2024/1722535548_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Waters among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$300.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Justin Bowers</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$310.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Puneet Souda</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$375.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$300.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$275.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$295.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$358.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$332.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$312.00</td>
<td>$319.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Waters. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Waters compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Waters's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Waters's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/WAT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Waters analyst ratings.</a>
<h2>Delving into Waters's Background</h2>
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.
<h3>A Deep Dive into Waters's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Waters's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -22.29%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Waters's net margin excels beyond industry benchmarks, reaching 16.05%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Waters's ROE stands out, surpassing industry averages. With an impressive ROE of 8.49%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Waters's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.24% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Waters's debt-to-equity ratio stands notably higher than the industry average, reaching 1.64. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Waters Stock

Barclays analyst Luke Sergott maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Underweight and raises the price target from $275 to $300.

Barclays Maintains Underweight on Waters, Raises Price Target to $300

Deutsche Bank analyst Justin Bowers maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Hold and lowers the price target from $330 to $310.

Deutsche Bank Maintains Hold on Waters, Lowers Price Target to $310

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Morgan Stanley raised the price target for Zeta Global Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) from $18 to $30. Morgan Stanley analyst Elizabeth Porter downgraded the stock from Overweight to Equal-Weight. Zeta Global shares rose 2.1% to close at $21.42 on Wednesday. <a href="https://www.benzinga.com/quote/ZETA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham boosted the price target for Glaukos Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NASDAQ">GKOS</a>) from $131 to $137. Needham analyst David Saxon maintained a Buy rating. Glaukos shares fell 0.6% to close at $117.17 on Wednesday. <a href="https://www.benzinga.com/quote/GKOS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities increased Day One Biopharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAWN#NASDAQ">DAWN</a>) price target from $11 to $24. B of A Securities analyst Alec Stranahan upgraded the stock from Underperform to Buy. Day One Biopharmaceuticals shares fell 5.8% to close at $14.31 on Wednesday. <a href="https://www.benzinga.com/quote/DAWN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt raised the price target for Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) from $562 to $643. Rosenblatt analyst Barton Crockett maintained a Buy rating. Meta shares gained 2.5% to close at $474.83 on Thursday.<a href="https://www.benzinga.com/quote/META/analyst-ratings"> See how other analysts view this stock.</a></li>
<li>Rosenblatt raised QUALCOMM Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) price target from $240 to $250. Rosenblatt analyst Kevin Cassidy maintained a Buy rating. QUALCOMM shares rose 8.4% to close at $180.95 on Wednesday. <a href="https://www.benzinga.com/quote/QCOM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities increased The Allstate Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) price target from $213 to $226. B of A Securities analyst Joshua Shanker maintained a Buy rating. Allstate shares fell 1.4% to close at $171.12 on Wednesday. <a href="https://www.benzinga.com/quote/ALL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley raised the price target for GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) from $175 to $220. Morgan Stanley analyst Andrew Percoco upgraded the stock from Equal-Weight to Overweight. GE Vernova shares gained 9.6% to close at $178.24 on Wednesday. <a href="https://www.benzinga.com/quote/GEV/analyst-ratings">See how other analysts view this stoc</a>k.</li>
<li>Baird boosted Generac Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) price target from $142 to $163. Baird analyst Michael Halloran maintained a Neutral rating. Generac shares rose 0.1% to close at $155.68 on Wednesday. <a href="https://www.benzinga.com/quote/GNRC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Loop Capital increased Pegasystems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) price target from $68 to $84. Loop Capital analyst Yun Kim upgraded the stock from Hold to Buy. Pegasystems shares fell 1.4% to close at $69.72 on Wednesday. <a href="https://www.benzinga.com/quote/PEGA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners boosted Waters Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) price target from $325 to $375. Leerink Partners analyst Puneet Souda upgraded the stock from Market Perform to Outperform. Waters shares gained 2.6% to close at $336.28 on Wednesday. <a href="https://www.benzinga.com/quote/WAT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Check This Out:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40092288/nasdaq-settles-higher-as-nvidia-records-best-session-since-february-fear-greed-index-now-in-neutral"> Nasdaq Settles Higher As Nvidia Records Best Session Since February: Fear &amp; Greed Index Now In &#8216;Neutral&#8217; Zone As Investor Sentiment Improves</a></li>
</ul>

Pre-Market Outlook

DAWN

GKOS

GNRC

PEGA

QCOM

ZETA

Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday

Leerink Partners analyst Puneet Souda upgrades Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) from Market Perform to Outperform and raises the price target from $325 to $375.

Leerink Partners Upgrades Waters to Outperform, Raises Price Target to $375

WIIM

Waters shares are trading higher after the company reported better-than-expected Q2 financial results.

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 1.5% on Wednesday.
Shares of Pinterest, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NASDAQ">PINS</a>) fell sharply in pre-market trading  after the company issued third-quarter revenue <a href="https://www.benzinga.com/news/earnings/24/07/40051745/pinterest-q2-earnings-revenue-eps-beat-but-weak-guidance-weighs-on-shares">guidance below estimates</a>.
Pinterest reported second-quarter revenue of $854 million, beating the consensus estimate of $847.81 million, according to Benzinga Pro. The idea discovery platform company reported adjusted earnings of 29 cents per share, beating analyst estimates of 28 cents per share, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Pinterest expects third-quarter revenue to be in the range of $885 million to $900 million versus estimates of $907.7 million.
Pinterest shares dipped 10.5% to $33.43 in the pre-market trading session.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>MacroGenics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) shares fell 24% to $3.99 in pre-market trading. The company announced a presentation of clinical data from the TAMARACK Phase 2 study of vobramitamab duocarmazine at the upcoming European Society for Medical Oncology Congress 2024.</li>
<li>Penumbra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) shares declined 20.3% to $137.93 in pre-market trading after the company reported second-quarter financial results and cut its FY24 revenue guidance below estimates.</li>
<li>Groupon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) shares tumbled 18.6% to $12.75 in pre-market trading following a second-quarter EPS miss.</li>
<li>Definitive Healthcare Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DH#NASDAQ">DH</a>) shares dipped 17.6% to $4.71 in pre-market trading. Needham analyst Ryan MacDonald reiterated Definitive Healthcare with a Hold.</li>
<li>O-I Glass, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OI#NYSE">OI</a>) declined 15.5% to $9.80 in pre-market trading after the company lowered its FY24 guidance.</li>
<li>Lemonade, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) shares fell 14.6% to $19.33 in pre-market trading following quarterly results.</li>
<li>Cantaloupe, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTLP#NASDAQ">CTLP</a>) fell 10.5% to $7.01 in pre-market trading.</li>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) fell 9.3% to $367.00 in pre-market trading following second-quarter results.</li>
<li>Axos Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AX#NYSE">AX</a>) declined 9% to $70.60 in pre-market trading following weak quarterly sales.             </li>
<li>SiteOne Landscape Supply, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SITE#NYSE">SITE</a>) dipped 8.2% to $131.77 in pre-market trading following second-quarter results.</li>
<li>Archrock, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AROC#NYSE">AROC</a>) dipped 7% to $20.00 in pre-market trading following weak quarterly results.</li>
<li>Waters Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) fell 6.9% to $305.00 in pre-market trading as the company lowered its FY24 outlook.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/40059087/nasdaq-tumbles-amid-decline-in-tech-stocks-greed-index-moves-to-fear-zone">Nasdaq Tumbles As Microsoft, Nvidia And Other Tech Stocks Decline: Greed Index Moves To &#8216;Fear&#8217; Zone</a></li>
</ul>

Movers

AROC

CTLP

GRPN

LMND

MGNX

PINS

SITE

Pinterest Issues Weak Revenue Forecast, Joins Groupon, O-I Glass And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Waters shares are trading lower after the company lowered its FY24 outlook and issued weak Q3 guidance.

Third Quarter 2024 Financial Guidance
The Company expects third quarter 2024 constant currency sales growth to be in the range of +1.0% to +3.0%. Currency translation is expected to decrease third quarter sales growth by approximately 1.5%. The resulting third quarter 2024 reported sales growth is expected in the range of -0.5% to +1.5%.
The Company expects third quarter 2024 non-GAAP EPS to be in the range of $2.60 to $2.70, which includes an estimated headwind of approximately 2% due to unfavorable foreign exchange.

Guidance

Waters Q3 Adj. EPS Outlook $2.60-$2.70 Vs. $2.89 Estimate

Full-Year and Third Quarter 2024 Financial Guidance
&nbsp;
Full-Year 2024 Financial Guidance
The Company now expects full-year 2024 organic constant currency sales growth to be in the range of -2.0% to -0.5%. Currency translation is expected to decrease full-year sales growth by approximately 1.5%. M&amp;A contribution from the Wyatt transaction covering the first four-and-a-half months of the year has added 1.3% to full-year reported sales. The resulting full-year 2024 reported sales growth is expected in the range of -2.2% to -0.7%.

Waters Lowers FY24 Outlook: Adj EPS From $11.75-12.05 to $1.55-$11.65 vs $11.78 Estimate; Sales Growth Outlook To -2.2% to -0.7%  vs $2.96B Estimate

Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) reported quarterly earnings of $2.63 per share which beat the analyst consensus estimate of $2.56 by 2.73 percent. This is a 6.07 percent decrease over earnings of $2.80 per share from the same period last year. The company reported quarterly sales of $708.529 million which beat the analyst consensus estimate of $700.079 million by 1.21 percent. This is a 4.33 percent decrease over sales of $740.576 million the same period last year.

Earnings Beats

Waters Q2 2024 Adj. EPS $2.63 Beats $2.56 Estimate, Sales $708.529M Beat $700.079M Estimate

Evercore ISI Group analyst Vijay Kumar maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a In-Line and lowers the price target from $320 to $300.

Evercore ISI Group Maintains In-Line on Waters, Lowers Price Target to $300

Across the recent three months, 6 analysts have shared their insights on Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $318.67, a high estimate of $358.00, and a low estimate of $275.00. Experiencing a 0.1% decline, the current average is now lower than the previous average price target of $319.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1719597615_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Waters. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$275.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$295.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$358.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$332.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$312.00</td>
<td>$319.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$340.00</td>
<td>$320.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Waters. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Waters compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Waters's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Waters's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/WAT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Waters analyst ratings.</a>
<h2>Unveiling the Story Behind Waters</h2>
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.
<h3>Waters: Delving into Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Waters's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -22.29% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Waters's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.05%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Waters's ROE excels beyond industry benchmarks, reaching 8.49%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Waters's ROA excels beyond industry benchmarks, reaching 2.24%. This signifies efficient management of assets and strong financial health.
Debt Management: Waters's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.64, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For Waters

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Waters (WAT – Research Report), Neurocrine (NBIX – Research Repor...

Analysts Offer Insights on Healthcare Companies: Waters (WAT), Neurocrine (NBIX) and Syndax Pharmaceuticals (SNDX)

Bristol-Myers tops growth chart among S&P 500 healthcare stocks in Q3

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Elanco Animal Health (ELAN – Research Report) and Wa...

Analysts Are Bullish on These Healthcare Stocks: Elanco Animal Health (ELAN), Waters (WAT)

Waters upgraded by Jefferies to buy on potential super cycle

In a report released today, Tycho Peterson from Jefferies upgraded Waters (WAT – Research Report) to a Buy, with a price target of $415.00. Tycho P...

Upgrading Waters: A Buy Rating on LC Replacement Cycle and Strong Sector Positioning

Spectris plc: It's A Great Time To Buy

Madison Mid Cap Fund Q3 2024 Investment Strategy Letter

Artisan Mid Cap Value Fund Q3 2024 Commentary

Waters Q3 2024 Earnings Preview

Here's the major earnings before the open tomorrow

ACDVF

APAM

ARCB

ARES

ASIX

ASML

ASMLF

BFLY

CBOE

CHTR

CMLS

CPRT

DBRG

DXCM

ELAN

ESNT

FUBO

GNTX

GTLS

INTT

LBRDA

MCHVF

MRNA

MSGS

NBIX

NTAP

OXLC

PCAR

PRLB

SEPJF

SEPJY

SNDX

SOLV

TROW

Commodities

Press Releases

Waters Corporation to Present at the Jefferies 2024 Healthcare Conference

Waters Becomes First Liquid Chromatography Column Provider to Receive My Green Lab ACT Ecolabel Certification

Waters Sets New Standards for High Resolution Performance and Speed with Xevo MRT Mass Spectrometer

Waters Corporation Schedules Second Quarter 2024 Earnings Conference Call

Waters New Rapid Screening-DSC Enables Up to 24x Faster Thermal Stability Testing at Ultra-Low Sample Volumes for Antibody Drugs

Waters Corporation (NYSE: WAT) Reports Second Quarter 2024 Financial Results

Waters Corporation Appoints Heather Knight to Board of Directors

Waters Corporation Schedules Third Quarter 2024 Earnings Conference Call

New Waters Discovery Core Rheometer Brings the Power of Rheology to Routine Quality Control Testing

Waters New Bioseparations Tools Accelerate and Improve Development of RNA-based Vaccines and Therapies Using LC-MS Analysis

Agilent Technologies

AbCellera Biologics

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Waters

Vendite allo scoperto

Waters (NYSE:WAT) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO